联用奥美沙坦对慢性心力衰竭患者治疗的有效性及安全性研究

摘要/Abstract

摘要： 目的探究联用奥美沙坦对慢性稳定期心力衰竭患者心功能、炎症因子及左室舒张功能的影响。方法选择2020年6月—2022年1月于扶风县人民医院接受治疗的80例慢性稳定期心力衰竭患者为研究对象,按照随机数表法将其分为研究组与对照组,每组40例。对比两组患者治疗效果差异,对比两组治疗前后心功能指标[左室后壁厚度（LVPWD）、室间隔厚度（LVEDD）]、炎症因子指标[白细胞介素-23（IL-23）、白细胞介素-6（IL-6）]、心肌损伤相关指标[长正五聚蛋白（PTX-3）、心型脂肪酸结合蛋白（H-FABP）]水平差异,并对比两组患者不良反应发生率。结果研究组患者治疗总有效率较对照组提高（P<0.05）。治疗前两组患者的LVPWD、LVEDD比较,差异无统计学意义（P>0.05）;治疗后研究组患者的LVPWD和LVEDD均低于对照组（P<0.05）。治疗前两组患者的IL-6和IL-23水平比较,差异无统计学意义（P>0.05）;治疗后研究组患者的IL-6水平低于对照组,IL-23水平高于对照组（P<0.05）。治疗前两组患者的PTX-3和H-FABP水平比较,差异无统计学意义（P>0.05）;治疗后研究组患者的PTX-3和H-FABP水平均低于对照组（P<0.05）。研究组不良反应总发生率与对照组比较,差异无统计学意义（P>0.05）。结论奥美沙坦对慢性稳定期心力衰竭具有较好的治疗效果,相较传统疗法,能够更好地缓解患者机体炎症状态和心肌损伤,同时治疗安全性也较高。

关键词: 奥美沙坦, 慢性稳定期心力衰竭, 心功能, 炎症因子, 心肌损伤, 临床疗效

Abstract: Objective To explore the effects of combined Olmesartan on cardiac function, inflammatory factors, and left ventricular diastolic function in patients with chronic stable heart failure. Methods The 80 chronic stable heart failure patients treated in Fufeng County People's Hospital from June 2020 to January 2022 were divided into the study group (n=40, adding Olmesartan based on the control group) and the control group (n=40, receiving conventional treatment alone). The treatment effect, the left ventricular posterior wall thickness (LVPWD), ventricular septal thickness (LVEDD), inflammatory factor interleukin-23 (IL-23), interleukin-6 (IL-6), myocardial injury-related protein (PTX-3), heart fatty acid binding protein (H-FABP) levels of two groups were compared, and counted the incidence of adverse reactions in the two groups of patients. Results The total treatment response rate of the study group was significantly higher than the control group (P<0.05); there was no significant difference between the LVEF and LVEDD groups in the two groups before the treatment (P>0.05), the LVPWD and LVEDD in the study group were lower than those in the control group (P<0.05); there was no significant difference in the IL-6 and IL-23 levels between the two patient groups before the treatment (P>0.05), IL-6 levels in patients were lower than in the control group, the IL-23 level was higher than that in the control group (P<0.05); there was no significant difference between the groups of PTX-3 and H-FABP levels in the two groups before the treatment (P>0.05), both PTX-3 and H-FABP were lower in the posttreated study group than in the control group (P<0.05); there was no significant difference between the total incidence of adverse reactions in the study group and the control patients (P>0.05). ConclusionOmesartan has a better treatment effect on chronic stable heart failure, compared with traditional therapy, it can better relieve the inflammatory state and myocardial injury of patients, and the treatment safety is also higher.

Key words: olmesartan, chronic stable phase of heart failure, heart function, inflammatory factors, myocardial injury, clinical efficacy

中图分类号:

R541

陈健, 李文静. 联用奥美沙坦对慢性心力衰竭患者治疗的有效性及安全性研究[J]. 中华养生保健, 2023, 41(6): 19-22.

CHEN Jian, LI Wen-jing. Efficacy and Safety of Olmesartan in Patients with Chronic Heart Failure[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(6): 19-22.

参考文献 20

[1]	夏勇,张建卿,王少霞,等.沙库巴曲缬沙坦联合琥珀酸美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病并慢性心力衰竭的效果观察[J].首都医科大学学报,2020,41(1):113-118.
[2]	崔玲玲,胡慧秀,孙超.慢性心力衰竭管理临床实践指南的质量评价与内容分析[J].中国护理管理,2021,21(2):243-248.
[3]	赵荫涛,裴小鑫,胡铂,等.Ghrelin对多柔比星诱导大鼠心力衰竭和心肌损伤的保护作用及机制[J].实用医学杂志,2021,37(1):30-34.
[4]	唐超,蔡琳,郭璐,等.胱抑素C与多发性肌炎/皮肌炎合并心力衰竭关系的横断面研究[J].中西医结合心脑血管病杂志,2019,17(23): 3740-3744.
[5]	刘姗姗,边素艳,王逸飞,等.老年心力衰竭住院患者基础病因及并发疾病分析[J].中华老年心脑血管病杂志,2022,24(4):359-362.
[6]	SEFEROVIĆ P M, VARDAS P, JANKOWSKA E A, et al.National Heart Failure Societies of the ESC member countries (see Appendix). The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019[J]. Eur J Heart Fail,2021,23(6):906-914.
[7]	张生长,黄伟剑.托拉塞米联合比索洛尔对原发性高血压合并收缩性心力衰竭患者的影响及不良反应分析[J].中国药物警戒,2019,16(8): 467-472.
[8]	中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.慢性心力衰竭基层诊疗指南(实践版·2019)[J].中华全科医师杂志,2019, 18(10):948-956.
[9]	毛银娟,杨礼,刘保民,等.心脏彩超评估高血压左心室肥厚伴左心衰竭患者心功能的临床价值及与NYHA分级的关系研究[J].现代生物医学进展,2019,19(23):4474-4478.
[10]	刘丹,顾佳宁,韩凯月,等.心脏核磁共振参数预测ST段抬高型心肌梗死患者急诊血运重建后心功能改善的价值[J].国际心血管病杂志,2021,48(3):184-188.
[11]	韦丙奇,王运红,黄燕,等.肥厚型心肌病心力衰竭呈扩张性心肌病改变与限制性心肌病改变患者的心脏结构和功能特点对比分析[J].中国循环杂志,2018,33(6):580-584.
[12]	张迪,石菲菲,辛雨,等.二肽基肽酶4抑制剂抑制Wnt/β-catenin信号通路改善慢性心力衰竭大鼠心肌纤维化[J].解剖科学进展,2019,25(4):390-394.
[13]	何刚,刘红旭,周琦,等.应用脉搏指示连续心排血量监测技术评价左西孟旦注射液联合参附注射液对重症射血分数降低型心力衰竭住院患者血流动力学的影响[J].中国医药,2020,15(4):508-512.
[14]	潘文麒,陆林.Vasostatin-2与心肌梗死患者慢性心力衰竭发生及预后的关系[J].检验医学,2022,37(7):623-627.
[15]	郑磊,候诚,李婴婴,等.中西医结合对老年心力衰竭伴呼吸道感染心肺功能及血清CRP、PCT、IL-6的影响分析[J].中华中医药学刊,2019,37(10):2529-2531.
[16]	郭雯,刘文娴,张维君,等.血管紧张素-(1-7)及丝裂原活化蛋白激酶激酶抑制剂U0126对血管紧张素Ⅱ诱导的大鼠右心室心肌成纤维细胞增殖的影响[J].中国医药,2021,16(2):302-305.
[17]	张婷婷,郭佳.基于心脏彩超评价银杏叶提取物联合奥美沙坦酯治疗慢性充血性心力衰竭的临床疗效[J].中西医结合心脑血管病杂志,2020,18(1):111-113.
[18]	赵勇,芦涤,刘涛,等.奥美沙坦联合比索洛尔治疗高血压心力衰竭的效果和安全性[J].心脑血管病防治,2019,19(4):330-332.
[19]	戴大银,邓学军,余冬梅.米力农与重组人脑利钠肽对慢性心力衰竭患者心脏结构及功能、炎症因子及RAAS的影响比较[J].实用药物与临床,2019,22(6):601-605.
[20]	黎晨辉,杨少芬,卢庆莉,等.系统免疫炎症指数与慢性心力衰竭急性发作患者院内死亡的相关性研究[J].心肺血管病杂志,2021, 40(7): 658-662.